The estimated Net Worth of John Frederick Harper is at least $2.84 Million dollars as of 14 August 2013. John Harper owns over 66,666 units of Axogen stock worth over $2,843,168 and over the last 12 years John sold AXGN stock worth over $0.
John has made over 2 trades of the Axogen stock since 2012, according to the Form 4 filled with the SEC. Most recently John bought 66,666 units of AXGN stock worth $199,998 on 14 August 2013.
The largest trade John's ever made was buying 86,557 units of Axogen stock on 1 October 2012 worth over $312,471. On average, John trades about 51,074 units every 106 days since 2012. As of 14 August 2013 John still owns at least 214,094 units of Axogen stock.
You can see the complete history of John Harper stock trades at the bottom of the page.
John's mailing address filed with the SEC is 13859 PROGRESS BLVD.,, SUITE 100, ALACHUA, FL, 32615.
Over the last 14 years, insiders at Axogen have traded over $73,805,978 worth of Axogen stock and bought 504,297 units worth $3,119,117 . The most active insiders traders include James E Deerfield Mgmt L.P...., Guido J Neels, and Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of $455,132. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth $158,085.
it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.
Axogen executives and other stock owners filed with the SEC include: